We are live on ! Find out more
BIS icon

ProShares UltraShort NASDAQ Biotechnology

3 hedge funds and large institutions have $671K invested in ProShares UltraShort NASDAQ Biotechnology in 2026 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

689% more capital inflows, than outflows

Capital inflows: $144K | Capital outflows: $18.3K

50% more funds holding

Funds holding: 2 → 3 (+1)

6.19% more ownership

Funds ownership: 30.1% → 36.29% (+6.2%)

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

Holders
3
Holders Change
+1
Holders Change %
+50%
% of All Funds
0.04%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
1
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Sellers

Rank Fund Capital Flow
1
Tower Research Capital (TRC)
Tower Research Capital (TRC)
New York
-$18.3K

BIS Hedge Fund Activity: Q3 2026 in Review

3 of the 8,154 institutional investors tracked by Wall St. Rank reported a position in ProShares UltraShort NASDAQ Biotechnology (BIS) for Q3 2026, worth a combined $671K — down 0.97% from $677K a quarter earlier.

Buyers outnumbered sellers: 1 fund opened new BIS positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 1 trimmed.

The largest buyer was Susquehanna International Group, adding an estimated $138K. The largest seller was Tower Research Capital (TRC), cutting an estimated $18.3K.

  • 3 institutional investors held ProShares UltraShort NASDAQ Biotechnology (BIS) as of Q3 2026, up from 2 in Q2 2026.
  • Funds reported $671K of ProShares UltraShort NASDAQ Biotechnology stock for Q3 2026, down 0.97% quarter-over-quarter.
  • 1 fund opened new ProShares UltraShort NASDAQ Biotechnology positions in Q3 2026 and 0 closed out, a net change of +1 holder.
  • The largest ProShares UltraShort NASDAQ Biotechnology buyer in Q3 2026 was Susquehanna International Group, an estimated $138K added.
  • The largest ProShares UltraShort NASDAQ Biotechnology seller in Q3 2026 was Tower Research Capital (TRC), an estimated $18.3K sold.

Based on aggregated 13F filings for Q3 2026.